12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

J&J, Shionogi deal

Shionogi granted Johnson & Johnson exclusive, worldwide rights to develop and commercialize Shionogi's oral beta secretase inhibitors for Alzheimer's disease. Shionogi will receive an undisclosed...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >